Stockscreener 앱 받기
118.86
0.76%
0.98
전일 마감가:
$117.88
열려 있는:
$117.12
하루 거래량:
271.44K
Relative Volume:
0.04
시가총액:
$147.41B
수익:
$28.80B
순이익/손실:
$6.31B
주가수익비율:
23.64
EPS:
5.0273
순현금흐름:
$9.37B
1주 성능:
-2.21%
1개월 성능:
+5.47%
6개월 성능:
+13.98%
1년 성능:
+34.85%
1일 변동 폭
$116.70
$118.96
1주일 범위
$116.70
$121.88
52주 변동 폭
$86.08
$124.61
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
GILD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
118.80 | 146.27B | 28.80B | 6.31B | 9.37B | 5.0273 |
|
LLY
Lilly Eli Co
|
820.19 | 735.18B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
186.11 | 450.37B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.15 | 401.96B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
122.69 | 238.94B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
87.65 | 217.38B | 63.43B | 16.42B | 14.72B | 6.4861 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Gilead Sciences (GILD) Reports Q3: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Income Plays: Is Gilead Sciences Inc. stock attractive for long term wealth buildingCEO Change & Smart Investment Allocation Insights - Fundação Cultural do Pará
Weekly Trades: How Gilead Sciences Inc. stock performs in rate cut cycles2025 Geopolitical Influence & Verified Short-Term Plans - Fundação Cultural do Pará
AmBisome Market 2025 Is Booming Worldwide by 2032 |Gilead Sciences Inc and Astellas Pharma Inc - openPR.com
Using data tools to time your Gilead Sciences Inc. exit2025 Key Highlights & High Accuracy Buy Signal Tips - newser.com
Is Gilead Sciences Inc. stock cheap at current valuation2025 Trading Volume Trends & Community Trade Idea Sharing - newser.com
Will Gilead Sciences Inc. (GIS) stock sustain dividend payoutsJuly 2025 Rallies & Community Trade Idea Sharing Platform - Fundação Cultural do Pará
François Cherifi: Deeply Grateful to Gilead Sciences for Awarding me the Gilead Scholarship at ESMO2025 - Oncodaily
Will Gilead Sciences Inc. stock remain a Wall Street favorite2025 Macro Impact & Free Accurate Trade Setup Notifications - newser.com
Exit strategy if you’re trapped in Gilead Sciences Inc.July 2025 Gainers & Growth Focused Entry Reports - newser.com
Is this a good reentry point in Gilead Sciences Inc.Earnings Performance Report & Risk Managed Investment Entry Signals - newser.com
Using economic indicators to assess Gilead Sciences Inc. potentialJuly 2025 Earnings & Reliable Trade Execution Plans - newser.com
Is Gilead Sciences Inc. stock attractive for long term wealth buildingJuly 2025 PostEarnings & Stepwise Trade Signal Guides - Fundação Cultural do Pará
Gilead Sciences’ GS-1219 HIV Study Update: Implications for Investors - TipRanks
What's in Store for These 5 Pharma Bigwigs This Earnings Season? - TradingView
Gilead Sciences: Strong Market Position and Growth Potential in HIV and PrEP with Promising Yeztugo Launch - TipRanks
Will Gilead Sciences Inc. stock sustain high P E ratiosJuly 2025 PreEarnings & Community Shared Stock Ideas - newser.com
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock announce a stock splitMarket Rally & High Accuracy Trade Signal Alerts - newser.com
Gilead Sciences VP Praises China's Reforms for Helping Launch More Novel Drugs - Yicai Global
Will Gilead Sciences Inc. outperform the marketEarnings Growth Report & Expert Verified Movement Alerts - newser.com
Is Gilead Sciences Inc. still worth holding after the dip2025 Trading Volume Trends & Community Trade Idea Sharing - newser.com
Is Gilead Sciences Inc. (Common Stock) (GIS0) stock a buy for dividend portfolios2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
What makes Gilead Sciences Inc. (Common Stock) (GIS0) stock appealing to growth investorsPortfolio Risk Summary & Real-Time Market Trend Scan - newser.com
How to build a dashboard for Gilead Sciences Inc. stockShare Buyback & Daily Profit Focused Screening - newser.com
Is Gilead Sciences Inc. (GIS) stock inflation resilientEarnings Summary Report & Verified High Yield Trade Plans - newser.com
Gilead Sciences Experiences Valuation Adjustment Amid Strong Market Performance and Metrics - Markets Mojo
Florida Settlement with Gilead Sciences for Improper Promotion of HIV Drugs - West Orlando News
Chart based exit strategy for Gilead Sciences Inc.Market Performance Summary & AI Forecasted Entry and Exit Points - newser.com
Gilead Sciences Stock Forecast: Where Analysts See the Stock Going by 2027 - TIKR.com
Morgan Stanley Remains Bullish on Gilead Sciences (GILD) - MSN
What To Expect From Gilead In Q3 2025 (NASDAQ:GILD) - Seeking Alpha
Gilead Sciences patents new PI3Kα inhibitors - BioWorld MedTech
Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - BioSpace
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know - sharewise.com
Precision Trading with Gilead Sciences Inc. (GILD) Risk Zones - news.stocktradersdaily.com
TD Cowen Raises Price Target for Gilead Sciences (GILD) to $125 - GuruFocus
Commentary: A breakthrough to prevent HIV shouldn’t break the bank - The Boston Globe
Gilead Sciences Rallies 32% in 2025 Are Shares Trading Below Their True Value - Yahoo Finance
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Wolfe Research Adjusts Gilead Sciences Price Target to $140 From $135, Maintains Outperform Rating - MarketScreener
TD Cowen Adjusts Gilead Sciences Price Target to $125 From $115, Maintains Buy Rating - MarketScreener
Gilead to present new data on Livdelzi for PBC at Liver Meeting 2025 - Investing.com
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
길리어드 사이언스 주식 (GILD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | Chief Financial Officer |
Oct 15 '25 |
Sale |
118.08 |
2,500 |
295,200 |
157,055 |
| Mercier Johanna | Chief Commercial Officer |
Oct 15 '25 |
Sale |
118.08 |
3,000 |
354,240 |
110,193 |
0.08%
0.16%
자본화:
|
볼륨(24시간):